Who founded Evolve Biosystems?

Evolve Biosystems was founded by J. Bruce German, David Mills, David J. Kyle in 2011.

Who are Evolve Biosystems's investors?

Evolve Biosystems's investors include iSelect Fund, Spruce Capital Partners.

How much funding has Evolve Biosystems raised?

Evolve Biosystems has disclosed $9M raised across 1 round.

Where is Evolve Biosystems headquartered?

Evolve Biosystems is headquartered in Davis, US.

Evolve Biosystems

Davis, US · Founded 2011 · Delaware corporation · 16 employees on LinkedIn · 2 known investors

Find your way into Evolve Biosystems

667 people in our graph share verified history with the Evolve Biosystems team — schools, employers, funds. One of them is your warm intro.

Charles Callunlockedknows David Mills · together at Montana State University-Bozeman (overlapped)

×3knows the team · via University of California, Davis

×2knows the team · via University of Wisconsin-Madison

knows the team · via University of Minnesota

knows the team · via Australian Institute of Company Directors

×2knows the team · via Montana State University-Bozeman

Evolve Biosystems develops probiotic strains of B. infantis, including EVC001 and a next-generation drug strain INF108, aimed at supporting the infant gut microbiome and preventing necrotizing enterocolitis (NEC) in premature infants. The company works at the intersection of breast milk research and infant health in the biotech and digital/medical therapeutics space.

Biotech Healthtech Medical Devices

Founders & leadership

Evolve Biosystems was founded in 2011 by J. Bruce German, David Mills, and David J. Kyle.

J. Bruce GermanCo-founder

David Mills in 𝕏Co-FounderDavid Mills is a Distinguished Professor of Food Science & Technology at UC Davis specializing in bacterial genomics and gut health. He has published over 240 peer-reviewed papers on lactic acid bacteria and bifidobacteria, co-founded the UC Davis Milk Group research consortium, and his research has informed the development of multiple biotechnology companies.

David J. Kyle inCo-founderDavid J. Kyle led research and commercial development at Martek Biosciences for over 15 years, where the company developed DHA and ARA ingredients for infant formulas before being acquired in 2011 for over $1B; he subsequently founded Advanced BioNutrition and joined Evolve Biosystems in 2013 as CEO, overseeing five venture capital rounds totaling $136M and the launch of the Evivo product line for infants.

John CampbellExecutive

James Campbell inCFO and Strategic Advisor2013–2016James Campbell is a biotechnology executive with a PhD in plant biochemistry from Deakin University and postdoctoral research at CERMAV CNRS in France, followed by roles as a research scientist at CSIRO and COO/CFO of ChemGenex Pharmaceuticals (ASX/NASDAQ-listed), where he supported growth from $10M to a $230M acquisition. He was a founding executive at Evolve Biosystems and has served as CEO of Patrys Limited and currently as CEO of Imitex Pty Ltd.

Board

Daniel JanneyBoard director

Simon BarnesBoard director

Catherine MackeyBoard director

Anne LoBoard director

Investors · 2

iSelect FundSt. Louis · $250K – $2M

Spruce Capital PartnersSouth San Francisco

Reported raises · per SEC filings

Form D private placements

$9M disclosed across 1 round · 2015

▶$9MraisedAug 2015 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Daniel JanneyDirector
John CampbellExecutive Officer
J. Bruce GermanDirector
James CampbellExecutive Officer
David MillsExecutive Officer
Catherine MackeyDirector
David J. KyleExecutive Officer, Director
Anne LoDirector
Simon BarnesDirector

Offering amount: $9M
Amount sold: $9M
First sale: Jul 2015
Incorporated: Corporation, Delaware, 2011
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Evolve Biosystems do?: Evolve Biosystems develops probiotic strains of B. infantis, including EVC001 and a next-generation drug strain INF108, aimed at supporting the infant gut microbiome and preventing necrotizing enterocolitis (NEC) in premature infants. The company works at the intersection of breast milk research and infant health in the biotech and digital/medical therapeutics space.
Who founded Evolve Biosystems?: Evolve Biosystems was founded by J. Bruce German, David Mills, David J. Kyle in 2011.
Who are Evolve Biosystems's investors?: Evolve Biosystems's investors include iSelect Fund, Spruce Capital Partners.
How much funding has Evolve Biosystems raised?: Evolve Biosystems has disclosed $9M raised across 1 round.
Where is Evolve Biosystems headquartered?: Evolve Biosystems is headquartered in Davis, US.